• Q4 FY25 revenue up 25.1% (17.9% in constant currency) versus pcp
• FY25 full year EBITDA expected towards top end of $7m to $9m guidance range
• FY25 full year positive free cash flow of $0.8m

SomnoMed Limited (ASX 'SOM' or the Company), the leading provider of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (OSA), has reported its quarterly activities for the period ended 30 June 2025 (Q4 FY25). Q4 FY25 revenue was $30.1m, up 25.1% (17.9% in constant currency) versus the previous corresponding period. Europe and North America continued to grow strongly, driven by a combination of price increases and new and returning customers. APAC demand moderated in Q4 after strong growth throughout the year, with Australia slowing post a price increase, but brand loyalty and medical referrals remain strong. The company has uplifted capacity to meet ongoing demand, and backlog has been reduced to negligible levels. It has also commenced works to further expand its facility to deliver additional capacity, with at least 25% expected to come online in FY26. For the full year FY25, the company expects revenue of $111.5m, up 21.6% (19.5% in constant currency), exceeding market guidance of greater than $105m. FY25 EBITDA is expected towards the top of the $7m to $9m guidance range, with positive free cash flow of $0.8m. The company also surpassed treating 1 million patients during FY25, confirming its global market leadership.

FY25 revenue of $111.5m, up 21.6% (+19.5% in constant currency) versus pcp and exceeding market guidance of greater than $105m. FY25 EBITDA expected towards the top of the $7m to $9m guidance range.

The company has commenced works to further expand the footprint of its facility to deliver additional capacity, with at least 25% expected to come online in FY26. It has also commenced a second round of cost optimisation, expected to be completed during FY26, which will enable further optimisation of resources and capability across the business.